<DOC>
	<DOCNO>NCT00809705</DOCNO>
	<brief_summary>This 3 arm , placebo-controlled study investigate effect Taspoglutide gastric empty patient type 2 diabetes . Patients randomize one 3 group receive ) 10mg Taspoglutide sc weekly 12 week b ) 10mg Taspoglutide sc weekly 4 week follow 20mg Taspoglutide sc weekly 8 week c ) placebo sc weekly 12 week , injection administer abdomen.Gastric emptying assess paracetamol test interval study . The anticipated time study treatment 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Effect Taspoglutide Gastric Emptying Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes mellitus , treat stable oral antidiabetic drug therapy &gt; =3 month prior screen ; stable weight +/10 % &gt; =3 month screen . type 1 diabetes mellitus ; acute gastrointestinal symptom screen and/or day 1 ; clinically relevant cardiovascular , bronchopulmonary , gastrointestinal neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>